B. Woodfall

发表

Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers

W. Brink, M. Peeters, M. Schöller-Gyüre, 2008, Journal of clinical pharmacology.

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

M. Peeters, M. Schöller-Gyüre, T. Kakuda, 2010, Clinical therapeutics.

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

M. Peeters, T. Kakuda, R. Hoetelmans, 2014, The Journal of antimicrobial chemotherapy.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

R. Haubrich, P. Cahn, T. Wilkin, 2007, The Lancet.

Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers

M. Peeters, M. Schöller-Gyüre, T. Kakuda, 2008, The Annals of pharmacotherapy.

A review of the safety and tolerability profile of the next-generation NNRTI etravirine.

G. di Perri, B. Grinsztejn, M. Peeters, 2010, AIDS research and human retroviruses.

Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV‐Infected Patients

K. Andries, M. Kukla, J. Vingerhoets, 2011 .

Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

J. Vingerhoets, T. Kakuda, W. Towner, 2010 .

Pharmacokinetics and Pharmacodynamics of the Non‐Nucleoside Reverse‐Transcriptase Inhibitor Etravirine in Treatment‐Experienced HIV‐1‐Infected Patients

E. Snoeck, J. Wade, M. Peeters, 2010, Clinical pharmacology and therapeutics.

Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2

G. di Perri, M. Peeters, J. Vingerhoets, 2010, HIV clinical trials.

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

A. Hill, M. Peeters, R. Hoetelmans, 2007, British journal of clinical pharmacology.

Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers

M. Peeters, M. Schöller-Gyüre, T. Kakuda, 2007, Antiviral therapy.

Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients

C. Katlama, M. Johnson, M. Peeters, 2008 .

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

B. Clotet, C. Katlama, M. Johnson, 2007, The Lancet.

Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects

Frank Goebel, F. Goebel, M. de Béthune, 2006, AIDS.

Lack of antiviral activity of darunavir against SARS-CoV-2

Denisa Bojkova, Christophe Buyck, S. Ciesek, 2020, International Journal of Infectious Diseases.

Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine

V. Vyncke, M. Boffito, A. Pozniak, 2008, Pharmacotherapy.

An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

B. Gazzard, S. Staszewski, A. Pozniak, 2003, AIDS.

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.

M. Peeters, M. Schöller-Gyüre, T. Kakuda, 2009, Contraception.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

R. Haubrich, B. Clotet, C. Katlama, 2010, Antiviral therapy.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2

M. Peeters, J. Vingerhoets, T. Kakuda, 2008 .

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

Hilde Azijn, M. de Béthune, M. Peeters, 2010, AIDS.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

R. Haubrich, C. Katlama, A. Lazzarin, 2009, AIDS.

Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

C. Cohen, M. de Béthune, D. Berger, 2009, AIDS.

Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

J. Montaner, E. Seminari, J. Gatell, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

D. Ward, C. Cohen, C. Hicks, 2007, AIDS.

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor‐naïve, nonnucleoside reverse transcriptase inhibitor‐experienced patients: study TMC125‐C227 *

K. Ruxrungtham, M. Peeters, J. Vingerhoets, 2008, HIV medicine.

Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients

A. Pozniak, M. Peeters, C. Workman, 2008, Antiviral therapy.

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

M. Peeters, M. Bouche, T. Kakuda, 2008, British journal of clinical pharmacology.

Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy

A. Rieger, M. de Béthune, A. Pozniak, 2008, Antiviral therapy.

K. Ruxrungtham, M. Peeters, J. Vingerhoets, 2008, HIV medicine.